Despite their widespread use, long-acting injectable (LAI) antipsychotics (APs) are often
regarded with some negativity because of the assumption of punishment, control and …

Objective: We reviewed important clinical aspects of bipolar depression, a progressive
psychiatric condition that is commonly treated in primary care. Bipolar depression is …

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published
treatment guidelines for bipolar disorder in 2005, along with international commentaries and …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Study quality is emerging as an essential component of evidence syntheses. It allows
practitioners and policymakers to make informed decisions based on the quality of the …

BACKGROUND: Antipsychotic medications are a central component of effective treatment
for schizophrenia, but nonadherence is a significant problem for the majority of patients …

Non-adherence is a major problem in the treatment of schizophrenia. Its high prevalence,
potentially severe consequences and associated costs make the study of this phenomenon …

Background Long-acting injectable (LAI) formulations are not widely used in routine practice
even though they offer advantages in terms of relapse prevention. As part of a process to …

Chronic insomnia is a significant public health problem worldwide, and insomnia has
considerable personal and social costs associated with serious health conditions, greater …

Objective: Nonadherence is a major challenge in schizophrenia treatment. While long-acting
(depot) antipsychotic medications are often recommended to address adherence problems …